. 2018 Jul 26;32(10):1086–1097. doi: 10.1177/0269881118788826

Table 3.

Meta-analysis of change from baseline in HAM-D single items at week 6/8 (FAS, MMRM, SES).

Item	Treatment ^a	All studies analysis (NCT00839423, NCT00635219, NCT00735709, NCT00672958, NCT00672620)					Three studies analysis (NCT00839423, NCT00635219, NCT00735709)
		N	∆ Placebo	SE	p-value	Heterogeneity p-value	N	∆ Placebo	SE	p-value	Heterogeneity p-value
4: Insomnia Early ^b	Placebo	691	·	·	·		338	·	·	·
	VOR 5 mg	714	−0.16	0.09	0.086	0.025	350	−0.28	0.08	<0.001	0.358
	VOR 10 mg	324	−0.35	0.08	<0.001	0.386	324	−0.35	0.08	<0.001	0.386
5: Insomnia Middle ^b	Placebo	691	·	·	·		338	·	·	·
	VOR 5 mg	714	−0.15	0.05	0.006	0.576	350	−0.23	0.08	0.003	0.985
	VOR 10 mg	324	−0.37	0.08	<0.001	0.815	324	−0.37	0.08	<0.001	0.815
6: Insomnia Late ^b	Placebo	691					338
	VOR 5 mg	714	−0.20	0.07	0.002	0.214	350	−0.29	0.09	<0.001	0.269
	VOR 10 mg	324	−0.25	0.12	0.038	0.088	324	−0.25	0.12	0.038	0.088
11: Anxiety Somatic ^b	Placebo	691	·	·	·		338	·	·	·
	VOR 5 mg	714	−0.15	0.08	0.059	0.078	350	−0.28	0.08	<0.001	0.678
	VOR 10 mg	324	−0.32	0.08	<0.001	0.356	324	−0.32	0.08	<0.001	0.356
12: Somatic Symptoms: Gastrointestinal ^b	Placebo	691	·	·	·		338	·	·	·
	VOR 5 mg	714	−0.11	0.07	0.091	0.205	350	−0.23	0.08	0.003	0.908
	VOR 10 mg	324	−0.26	0.18	0.153	0.005	324	−0.26	0.18	0.153	0.005
13: Somatic Symptoms: General ^b	Placebo	691	·	·	·		338	·	·	·
	VOR 5 mg	714	−0.17	0.07	0.013	0.154	350	−0.28	0.08	<0.001	0.411
	VOR 10 mg	324	−0.27	0.08	<0.001	0.408	324	−0.27	0.08	<0.001	0.408
14: Genital Symptoms ^b	Placebo	691	·	·	·		338	·	·	·
	VOR 5 mg	714	−0.20	0.10	0.052	0.007	350	−0.37	0.08	<0.001	0.853
	VOR 10 mg	324	−0.38	0.08	<0.001	0.803	324	−0.38	0.08	<0.001	0.803
16: Loss of Weight ^b	Placebo	691	·	·	·		338	·	·	·
	VOR 5 mg	714	−0.11	0.08	0.208	0.050	350	−0.04	0.08	0.620	0.941
	VOR 10 mg	324	−0.09	0.08	0.249	0.830	324	−0.09	0.08	0.249	0.830
HAM-D24 total score	Placebo	691					338
	VOR 5 mg	714	−0.32	0.11	0.003	0.004	350	−0.47	0.09	<0.001	0.230
	VOR 10 mg	324	−0.58	0.15	<0.001	0.026	324	−0.58	0.15	<0.001	0.026

The 10 mg vortioxetine (VOR) dose was tested only in the three positive studies; thus, the data in the 10 mg dose rows for the ‘All studies’ and the ‘Three studies’ analyses are identical.

Definition of item provided in Table 2.